Full-Service Commercial episode artwork

EPISODE · Sep 21, 2022 · 20 MIN

Full-Service Commercial

from The Syneos Health Podcast · host Jeffrey Stewart

Early stage biotech companies have traditionally had limited options to get their first asset to market: in most cases, they pursue deals with larger partners, losing control of their intellectual property and limiting their future financial returns, or become a fully integrated company through heavy investment and a great deal of risk. Opportunities for outsourcing some—or all—of a company’s commercial operations can be an option, but many companies have misconceptions about the highly viable “third option” of commercializing with a proven outsourced partner.Lee Taurman, Executive Vice President and Head, Full-Service Commercial and Carl Sailer, Vice President and Global Go-to-Market Lead, both from Syneos Health, discuss the wide range of outsourcing options companies can consider that reduce risk, manage costs and optimize performance while maintaining control of their asset—while debunking some of the myths associated with this alternative path to market.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. For more on commercial options for biotech companies on the verge of market entry, check out these insights:ON-DEMAND WEBINAR: Preparing and Aligning Your Biotech Organization for Commercial SuccessPRESENTATION: Investing for Commercial Success as an Emerging CompanyFive Considerations for Choosing an Agency Partner for a Successful Biopharma LaunchHow Clarity Can Be a Differentiator for Biotechs in Uncertain TimesIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected]. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected]

Early stage biotech companies have traditionally had limited options to get their first asset to market: in most cases, they pursue deals with larger partners, losing control of their intellectual property and limiting their future financial returns, or become a fully integrated company through heavy investment and a great deal of risk. Opportunities for outsourcing some—or all—of a company’s commercial operations can be an option, but many companies have misconceptions about the highly...

NOW PLAYING

Full-Service Commercial

0:00 20:25

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Syneos Health Podcast?

This episode is 20 minutes long.

When was this The Syneos Health Podcast episode published?

This episode was published on September 21, 2022.

What is this episode about?

Early stage biotech companies have traditionally had limited options to get their first asset to market: in most cases, they pursue deals with larger partners, losing control of their intellectual property and limiting their future financial...

Can I download this The Syneos Health Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!